Collaborating with the German family-controlled drug maker on OSE’s novel checkpoint inhibitor aligns with French firm’s strategy of partnering its portfolio candidates.
OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List
By Michael Tattory|
2018-04-27T12:26:49-04:00
April 9th, 2018|News|Comments Off on OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List